Abstract
Background: COVID-19 is still causing long-term health consequences, mass deaths, and
collapsing healthcare systems around the world. There are no efficient drugs for its treatment. However,
previous studies revealed that SARS-CoV-2 and SARS-CoV have 96% and 86.5% similarities in
cysteine proteases (3CLpro) and papain-like protease (PLpro) sequences, respectively. This resemblance
could be important in the search for drug candidates with antiviral effects against SARS-CoV-2.
Objective: This paper is a compilation of natural products that inhibit SARS-CoV 3CLpro and PLpro
and, concomitantly, reduce inflammation and/or modulate the immune system as a perspective strategy
for COVID-19 drug discovery. It also presents in silico studies performed on these selected natural
products using SARS-CoV-2 3CLpro and PLpro as targets to propose a list of hit compounds.
Methods: The plant metabolites were selected in the literature based on their biological activities on
SARS-CoV proteins, inflammatory mediators, and immune response. The consensus docking analysis
was performed using four different packages.
Results: Seventy-nine compounds reported in the literature with inhibitory effects on SARS-CoV proteins
were reported as anti-inflammatory agents. Fourteen of them showed immunomodulatory effects in
previous studies. Five and six of these compounds showed significant in silico consensus as drug candidates
that can inhibit PLpro and 3CLpro, respectively. Our findings corroborated recent results reported on
anti-SARS-CoV-2 in the literature.
Conclusion: This study revealed that amentoflavone, rubranoside B, savinin, psoralidin, hirsutenone,
and papyriflavonol A are good drug candidates for the search of antibiotics against COVID-19.
Keywords:
Natural products, COVID-19, 3CLpro and PLpro inhibitory effect, anti-inflammatory effect, immunomodulatory effect, drug discovery.
[10]
Hung, I.F.; Lung, K.C.; Tso, E.Y.; Liu, R.; Chung, T.W.; Chu, M.Y.; Ng, Y.Y.; Lo, J.; Chan, J.; Tam, A.R.; Shum, H.P.; Chan, V.; Wu, A.K.L.; Sin, K.M.; Leung, W.S.; Law, W.L.; Lung, D.C.; Sin, S.; Yeung, P.; Yip, C.C.Y.; Zhang, R.R.; Fung, A.Y.F.; Yan, E.Y.W.; Leung, K.H.; Ip, J.D.; Chu, A.W.H.; Chan, W.M.; Ng, A.C.K.; Lee, R.; Fung, K.; Yeung, A.; Wu, T.C.; Chan, J.W.M.; Yan, W.W.; Chan, W.M.; Chan, J.F.W.; Lie, A.K.W.; Tsang, O.T.Y.; Cheng, V.C.C.; Que, T.L.; Lau, C.S.; Chan, K.H.; To, K.K.W.; Yuen, K.Y. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: An open-label, randomised, phase 2 trial.
Lancet, 2020,
395(10238), 1695-1704.
[
http://dx.doi.org/10.1016/S0140-6736(20)31042-4] [PMID:
32401715]
[72]
Lissoni, P.; Rovelli, F.; Pelizzoni, F.; Lissoni, A.; Fede, G.D. Coronavirus-induced severe acute respiratory syndrome (SARS) as a possible expression of fatty acid amide hydrolase (FAAH) hyper-activation and possible therapeutic role of FAAH inhibitors in COVID 19-induced SARS. J. Clin. Res. Reports, 2020, 5(2)
[78]
Ziegler, C.G.K.; Allon, S.J.; Nyquist, S.K.; Mbano, I.M.; Miao, V.N.; Tzouanas, C.N.; Cao, Y.; Yousif, A.S.; Bals, J.; Hauser, B.M.; Feldman, J.; Muus, C.; Wadsworth, M.H., II; Kazer, S.W.; Hughes, T.K.; Doran, B.; Gatter, G.J.; Vukovic, M.; Taliaferro, F.; Mead, B.E.; Guo, Z.; Wang, J.P.; Gras, D.; Plaisant, M.; Ansari, M.; Angelidis, I.; Adler, H.; Sucre, J.M.S.; Taylor, C.J.; Lin, B.; Waghray, A.; Mitsialis, V.; Dwyer, D.F.; Buchheit, K.M.; Boyce, J.A.; Barrett, N.A.; Laidlaw, T.M.; Carroll, S.L.; Colonna, L.; Tkachev, V.; Peterson, C.W.; Yu, A.; Zheng, H.B.; Gideon, H.P.; Winchell, C.G.; Lin, P.L.; Bingle, C.D.; Snapper, S.B.; Kropski, J.A.; Theis, F.J.; Schiller, H.B.; Zaragosi, L.E.; Barbry, P.; Leslie, A.; Kiem, H.P.; Flynn, J.L.; Fortune, S.M.; Berger, B.; Finberg, R.W.; Kean, L.S.; Garber, M.; Schmidt, A.G.; Lingwood, D.; Shalek, A.K.; Ordovas-Montanes, J. HCA SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues.
Cell, 2020,
181(5), 1016-1035.e19.
[
http://dx.doi.org/10.1016/j.cell.2020.04.035] [PMID:
32413319]
[138]
He, P.; Ye, F.; Huang, S.; Guo, Y.; Wang, H.; Wu, Y. Anti-inflammatory effect of pristimerin on TNFα-induced inflammatory responses in murine macrophages. Int. J. Clin. Exp. Pathol., 2016, 9(2), 1186-1194.
[178]
Liu, J.J.; Liu, X.K. Chemical constituents from edible part of Pistacia chinensis. Chin. Tradit. Herbal Drugs, 2009, 40, 186-189.
[201]
Sargis, D.; Arthur, J. Small-Molecule Library Screening by Docking with PyRx. Chem. Biol., 2014, 1263, 243-250.